GT200600089A - Compuestos organicos - Google Patents
Compuestos organicosInfo
- Publication number
- GT200600089A GT200600089A GT200600089A GT200600089A GT200600089A GT 200600089 A GT200600089 A GT 200600089A GT 200600089 A GT200600089 A GT 200600089A GT 200600089 A GT200600089 A GT 200600089A GT 200600089 A GT200600089 A GT 200600089A
- Authority
- GT
- Guatemala
- Prior art keywords
- compounds
- tri
- substituted
- treatment
- organic compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
ESTA INVENCIÓN SE RELACIONA A LOS NUEVOS COMPUESTOS DE PIRROLIDINAS (3,4-DI-, 3,3,4-TRI, 3,4,4-TRI- O 3,3,4,4,-TETRA-) SUSTITUIDOS DE FÓRMULA (I), A SU USO PARA LA PREPARACIÓN DE FORMULACIONES FARMACÉUTICAS ÚTILES EN EL TRATAMIENTO DE ENFERMEDADES, TRATAMIENTOS DIAGNÓSTICOS Y TERAPÉUTICOS QUE DEPENDEN DE LA ACTIVIDAD DE LA RENINA, EN ANIMALES DE SANGRE CALIENTE. SE CONTEMPLA EL MÉTODO DE TRATAMIENTO QUE COMPRENDE ADMINISTRAR DICHOS COMPUESTOS SUSTITUIDOS DE PIRROLIDINA, UN MÉTODO PARA LA MANUFACTURA ESPECIALMENTE DE DICHOS COMPUESTOS, INTERMEDIARIOS NOVEDOSOS, MATERIALES DE INICIO Y/O PASOS PARCIALES PARA SUS SÍNTESIS. T2006
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0505969.6A GB0505969D0 (en) | 2005-03-23 | 2005-03-23 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600089A true GT200600089A (es) | 2006-11-08 |
Family
ID=34531739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600089A GT200600089A (es) | 2005-03-23 | 2006-02-22 | Compuestos organicos |
Country Status (26)
Country | Link |
---|---|
US (1) | US7807709B2 (es) |
EP (1) | EP1863477B1 (es) |
JP (1) | JP5171612B2 (es) |
KR (1) | KR20070113254A (es) |
CN (1) | CN101146530B (es) |
AR (1) | AR053832A1 (es) |
AT (1) | ATE486597T1 (es) |
AU (1) | AU2006226554B2 (es) |
BR (1) | BRPI0609671A2 (es) |
CA (1) | CA2600063A1 (es) |
DE (1) | DE602006017980D1 (es) |
ES (1) | ES2355742T3 (es) |
GB (1) | GB0505969D0 (es) |
GT (1) | GT200600089A (es) |
IL (1) | IL185242A0 (es) |
MA (1) | MA29379B1 (es) |
MX (1) | MX2007011694A (es) |
NO (1) | NO20075365L (es) |
PE (1) | PE20061325A1 (es) |
PL (1) | PL1863477T3 (es) |
PT (1) | PT1863477E (es) |
RU (1) | RU2419606C2 (es) |
TN (1) | TNSN07361A1 (es) |
TW (1) | TW200700061A (es) |
WO (1) | WO2006100036A1 (es) |
ZA (1) | ZA200706697B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
EP1968940B1 (en) | 2005-12-30 | 2014-04-02 | Novartis AG | 3 , 5-substitued piperidine compounds as renin inhibitors |
GB0611696D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
EP2119702A4 (en) | 2007-01-31 | 2010-12-08 | Dainippon Sumitomo Pharma Co | amide derivative |
EP2181105B1 (en) | 2007-06-25 | 2015-04-29 | Novartis AG | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
AU2011245987B2 (en) | 2010-04-28 | 2016-12-15 | Kyowa Hakko Kirin Co., Ltd | Cationic lipid |
PT2687518T (pt) * | 2011-03-16 | 2018-01-19 | Mitsubishi Tanabe Pharma Corp | Composto heterocíclico saturado contendo azoto |
JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
AU2012353463B2 (en) | 2011-12-12 | 2017-08-24 | Kyowa Hakko Kirin Co., Ltd. | Lipid nanoparticles containing combinations of cationic lipids |
CN103420890B (zh) * | 2012-05-15 | 2015-06-24 | 天津药物研究院 | 3-吡咯甲酸衍生物及其制备方法和用途 |
EP2873732A4 (en) | 2012-07-16 | 2016-03-23 | Kyowa Hakko Kirin Co Ltd | PHARMACEUTICAL RNAI COMPOSITION WITH SUPPRESSION OF KRAS GENE EXPRESSION |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
JP6743015B2 (ja) | 2014-12-15 | 2020-08-19 | バイエル ファーマ アクチエンゲゼルシャフト | Ksp阻害剤の脱グリコシル化抗tweakr抗体との抗体薬物複合体(adc類) |
CN114917361A (zh) | 2015-06-22 | 2022-08-19 | 拜耳医药股份有限公司 | 具有酶可裂解基团的抗体药物缀合物(adc)和抗体前药缀合物(apdc) |
CA2990394A1 (en) | 2015-06-23 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
EP3558387B1 (de) | 2016-12-21 | 2021-10-20 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
EP3558388A1 (de) | 2016-12-21 | 2019-10-30 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen |
CA3165101A1 (en) * | 2019-12-20 | 2021-06-24 | Arbutus Biopharma Corporation | Synthetic processes and intermediates |
CN111423411B (zh) * | 2020-04-02 | 2021-04-16 | 南京生命源医药科技有限公司 | 一种新型肾素抑制剂 |
WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0242789A3 (en) | 1986-04-25 | 1990-09-05 | Dainippon Pharmaceutical Co., Ltd. | Novel quinoline derivates and processes for preparation thereof |
ZA929788B (en) | 1991-12-18 | 1993-06-22 | Schering Corp | Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring. |
IL111176A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them |
JP2001526178A (ja) | 1997-08-28 | 2001-12-18 | メルク エンド カムパニー インコーポレーテッド | ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤 |
US6429213B1 (en) | 1998-06-17 | 2002-08-06 | Bristol Myers Squibb Pharma Co | Cyclic hydroxamic acids as metalloproteinase inhibitors |
US6610692B1 (en) | 1998-10-30 | 2003-08-26 | Merck & Co., Inc. | Thrombin inhibitors |
WO2000051608A1 (en) | 1999-03-02 | 2000-09-08 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
US6372764B1 (en) | 1999-03-02 | 2002-04-16 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
AU3386500A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
AU3386400A (en) * | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
CN1481377A (zh) | 2000-03-17 | 2004-03-10 | ����˹�ж�-����˹˹����ҩƷ��˾ | 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物 |
FR2811673B1 (fr) * | 2000-07-17 | 2002-09-13 | Rhodia Chimie Sa | Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes |
EP1326619A2 (en) | 2000-10-11 | 2003-07-16 | Merck & Co., Inc. | Pyrrolidine modulators of ccr5 chemokine receptor activity |
AU2002341715A1 (en) | 2001-09-17 | 2003-04-01 | Bristol-Myers Squibb Company | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
WO2003031443A1 (en) | 2001-10-04 | 2003-04-17 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety |
AU2003301959A1 (en) * | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
GB0212410D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Organic compounds |
EP1656368A4 (en) | 2002-07-09 | 2009-08-26 | Bristol Myers Squibb Co | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS AND ANTIABESITY AND THEIR MANUFACTURING PROCESS |
RU2413716C2 (ru) * | 2003-11-26 | 2011-03-10 | Новартис Аг | АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ |
BRPI0507067A (pt) | 2004-01-23 | 2007-06-12 | Speedel Experimenta Ag | diamino álcoois e seu uso como inibidores de renina |
US7767690B2 (en) | 2004-01-23 | 2010-08-03 | Novartis Ag | Amino alcohol derivatives and their use as renin inhibitor |
US7786307B2 (en) | 2004-01-23 | 2010-08-31 | Novartis Ag | Amino alcohol derivatives and their activity as renin inhibitors |
EP1725530A1 (en) | 2004-03-19 | 2006-11-29 | Speedel Experimenta AG | Organic compounds |
TW200536539A (en) | 2004-03-19 | 2005-11-16 | Speedel Experimenta Ag | Organic compounds |
CN1273452C (zh) * | 2004-06-01 | 2006-09-06 | 中国医学科学院医药生物技术研究所 | 7-(4,4-二甲基-3-氨甲基吡咯烷-1-基)取代的新喹啉羧酸衍生物及其制法 |
TW200631929A (en) | 2004-12-10 | 2006-09-16 | Speedel Experimenta Ag | ω -phenyloctanamides |
GB0428526D0 (en) * | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
US20080176947A1 (en) | 2005-03-11 | 2008-07-24 | Peter Herold | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors |
-
2005
- 2005-03-23 GB GBGB0505969.6A patent/GB0505969D0/en not_active Ceased
-
2006
- 2006-02-22 GT GT200600089A patent/GT200600089A/es unknown
- 2006-03-21 EP EP06707621A patent/EP1863477B1/en active Active
- 2006-03-21 US US11/909,402 patent/US7807709B2/en not_active Expired - Fee Related
- 2006-03-21 KR KR1020077021868A patent/KR20070113254A/ko not_active Application Discontinuation
- 2006-03-21 CA CA002600063A patent/CA2600063A1/en not_active Abandoned
- 2006-03-21 CN CN2006800094939A patent/CN101146530B/zh not_active Expired - Fee Related
- 2006-03-21 DE DE602006017980T patent/DE602006017980D1/de active Active
- 2006-03-21 AT AT06707621T patent/ATE486597T1/de active
- 2006-03-21 PT PT06707621T patent/PT1863477E/pt unknown
- 2006-03-21 AR ARP060101103A patent/AR053832A1/es unknown
- 2006-03-21 MX MX2007011694A patent/MX2007011694A/es active IP Right Grant
- 2006-03-21 BR BRPI0609671-9A patent/BRPI0609671A2/pt not_active IP Right Cessation
- 2006-03-21 AU AU2006226554A patent/AU2006226554B2/en not_active Ceased
- 2006-03-21 JP JP2008502310A patent/JP5171612B2/ja not_active Expired - Fee Related
- 2006-03-21 PL PL06707621T patent/PL1863477T3/pl unknown
- 2006-03-21 WO PCT/EP2006/002578 patent/WO2006100036A1/en active Application Filing
- 2006-03-21 RU RU2007138892/04A patent/RU2419606C2/ru not_active IP Right Cessation
- 2006-03-21 ES ES06707621T patent/ES2355742T3/es active Active
- 2006-03-22 TW TW095109927A patent/TW200700061A/zh unknown
- 2006-03-23 PE PE2006000322A patent/PE20061325A1/es not_active Application Discontinuation
-
2007
- 2007-08-13 IL IL185242A patent/IL185242A0/en unknown
- 2007-08-13 ZA ZA200706697A patent/ZA200706697B/xx unknown
- 2007-09-21 TN TNP2007000361A patent/TNSN07361A1/en unknown
- 2007-10-02 MA MA30268A patent/MA29379B1/fr unknown
- 2007-10-19 NO NO20075365A patent/NO20075365L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1863477B1 (en) | 2010-11-03 |
TW200700061A (en) | 2007-01-01 |
KR20070113254A (ko) | 2007-11-28 |
PT1863477E (pt) | 2011-02-10 |
DE602006017980D1 (de) | 2010-12-16 |
US20080194549A1 (en) | 2008-08-14 |
CA2600063A1 (en) | 2006-09-28 |
TNSN07361A1 (en) | 2008-12-31 |
MX2007011694A (es) | 2007-11-15 |
CN101146530A (zh) | 2008-03-19 |
PE20061325A1 (es) | 2007-01-05 |
WO2006100036A1 (en) | 2006-09-28 |
AU2006226554A1 (en) | 2006-09-28 |
RU2419606C2 (ru) | 2011-05-27 |
PL1863477T3 (pl) | 2011-04-29 |
ATE486597T1 (de) | 2010-11-15 |
EP1863477A1 (en) | 2007-12-12 |
JP2008534457A (ja) | 2008-08-28 |
ZA200706697B (en) | 2008-10-29 |
MA29379B1 (fr) | 2008-04-01 |
JP5171612B2 (ja) | 2013-03-27 |
IL185242A0 (en) | 2008-06-05 |
AR053832A1 (es) | 2007-05-23 |
US7807709B2 (en) | 2010-10-05 |
RU2007138892A (ru) | 2009-04-27 |
CN101146530B (zh) | 2011-05-18 |
BRPI0609671A2 (pt) | 2010-04-20 |
GB0505969D0 (en) | 2005-04-27 |
AU2006226554B2 (en) | 2010-03-11 |
ES2355742T3 (es) | 2011-03-30 |
NO20075365L (no) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600089A (es) | Compuestos organicos | |
GT200500359A (es) | Compuestos organicos | |
PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
ECSP088821A (es) | Derivados de tioxantina y su uso como inhibidores de la mpo | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
GT200500307A (es) | Compuestos quimicos | |
CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
UY28369A1 (es) | Agentes terapéuticos | |
ECSP088869A (es) | Derivados de 2-pirazinona para el tratamiento de enfermedades o condiciones en donde resulta beneficiosa la inhibición de la actividad de la elastasa neutrofílica | |
CU23831B1 (es) | Compuestos de pirrolo-pirimidina | |
NI200900091A (es) | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)- fenil]-propionitrilo | |
UY28314A1 (es) | Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad | |
CR10091A (es) | Compuestos orgánicos | |
CR9034A (es) | Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de la obesidad | |
NI200900145A (es) | Formulaciones de dosis unitaria y metodos para el tratamiento de la trombosis con un inhibidor oral del factor xa. | |
ECSP077324A (es) | Amidas bicíclicas como inhibidores de cinasa | |
UY28708A1 (es) | Heterociclos sustituídos y usos de los mismos | |
PA8586001A1 (es) | Derivados de indol útiles para el tratamiento de enfermedades | |
UY30094A1 (es) | Compuestos químicos | |
PA8803201A1 (es) | Derivados acidos de cicloalquilamino | |
UY28945A1 (es) | Derivados de pirrolopiridina | |
CY1109732T1 (el) | Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου | |
CR10336A (es) | Compuestos organicos y sus usos | |
PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica |